Bli medlem
Bli medlem

Du är här


XBiotech, Inc: XBiotech Names Industry Veteran Dawn McCollough to Head Clinical Operations

AUSTIN, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT), the
developer of True Human(TM) therapeutic antibodies, today announced that Dawn
McCollough has joined the company as Vice President of Clinical Operations,
effective May 16. McCollough has more than two decades of global industry
experience and has overseen all phases of clinical trial drug development
across multiple therapeutic areas.

Reporting to XBiotech Founder, President and Chief Executive Officer John
Simard, McCollough will lead clinical operations for XBiotech's extensive
portfolio of True Human antibody therapies, including Xilonix(TM), the
Company's lead candidate currently in late-stage development for the
treatment of advanced colorectal cancer.

"Dawn has overseen clinical trials involving thousands of patients across
multiple indications and stages of development," Simard said. "She thus
brings extraordinary experience to our clinical operations. I am delighted to
bring her energy and enthusiasm to the XBiotech leadership team."

McCollough joins XBiotech from Biogen, Inc., where she served as head of
Medical Research Operations and led the Medical Research team, which included
the company's Clinical Trial Review Committee. Prior to Biogen, McCollough
was head of the Global Monitoring Organization for North America at Novartis
Vaccines and Diagnostics, Inc., based in Cambridge, Mass. McCollough began
her Novartis career in their Vaccines and Diagnostics division in Siena,
Italy, as Global Head of Clinical Trial Governance. She has been recognized
consistently for her high performance and was chosen as a top Women's Leader
by both companies.

"I am excited to join XBiotech in advancing the Company's innovative True
Human therapeutic antibodies through the clinical process across multiple
therapeutic areas. My focus will be on demonstrating our commitment to our
investigators and patients in the continued development of potentially
groundbreaking new medicines."

XBiotech's lead product candidate, Xilonix, has the potential to change the
standard of care in treating advanced colorectal cancer. Currently in Phase
III clinical trials in the U.S. with Fast Track designation from the U.S.
Food and Drug Administration, Xilonix is specifically designed to target and
neutralize interleukin-1 alpha (IL-1a), a molecule known to promote
angiogenesis (the growth and spread of tumors), as well as mediate symptoms
such as metabolic dysregulation (e.g., a cause of muscle loss and weight
loss), fatigue and anxiety associated with advanced cancer.

About True Human(TM) Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech's True Human(TM)
antibodies are 100 percent human, derived from individuals who possess
natural immunity to certain diseases. With discovery and clinical programs
across multiple disease areas, XBiotech's True Human antibodies have the
potential to harness the body's natural immunity to fight disease with
increased safety, efficacy and tolerability.

The first of these therapies, Xilonix(TM), for advanced colorectal cancer, is
in Phase III clinical trials in the United States with a Fast Track
designation by the U.S. Food and Drug Administration (FDA). In Europe,
Xilonix Phase III clinical trials have been completed, and the therapy is
under accelerated review following the validation of its Market Authorization
Application by the European Medicines Agency (EMA).

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of therapeutic
antibodies based on its True Human(TM) proprietary technology. XBiotech
currently is advancing a robust pipeline of antibody therapies to exceed the
standards of care in oncology, inflammatory conditions and infectious
diseases. Headquartered in Austin, Texas, XBiotech also is leading the
development of innovative biotech manufacturing technologies designed to more
rapidly, cost-effectively and flexibly produce new therapies urgently needed
by patients worldwide. For more information, visit

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, including declarations
regarding management's beliefs and expectations that involve substantial
risks and uncertainties. In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "would," "could,"
"expects," "plans," "contemplate," "anticipates," "believes," "estimates,"
"predicts," "projects," "intend" or "continue" or the negative of such terms
or other comparable terminology, although not all forward-looking statements
contain these identifying words. Forward-looking statements are subject to
inherent risks and uncertainties in predicting future results and conditions
that could cause the actual results to differ materially from those projected
in these forward-looking statements. These risks and uncertainties are
subject to the disclosures set forth in the "Risk Factors" section of certain
of our SEC filings. Forward-looking statements are not guarantees of future
performance, and our actual results of operations, financial condition and
liquidity, and the development of the industry in which we operate, may
differ materially from the forward-looking statements contained in this press
release. Any forward-looking statements that we make in this press release
speak only as of the date of this press release. We assume no obligation to
update our forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.

Media liaison U.S.

Mariann Caprino


Media liaison ex-U.S.
Jonathan Kearney
+44 20 8618 2755; Mobile: +44 7725 925 841


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.